Literature DB >> 17558255

The negative syndrome as a dimension: factor analyses of PANSS in major depressive disorder and organic brain disease compared with negative syndrome structures found in the schizophrenia literature.

Matthew S Milak1, Dmitry B Aniskin, Daniel P Eisenberg, Alexander Prikhojan, Lisa J Cohen, Samantha S Yard, Igor I Galynker.   

Abstract

OBJECTIVE: To explore the concept of the negative syndrome as a dimensional entity that exists in multiple primary diagnoses, and to compare the negative syndrome in nonschizophrenic disorders and schizophrenia.
BACKGROUND: Although initially considered specific to schizophrenia, the negative syndrome has subsequently been described in major depression, stroke, and dementia.
METHOD: We performed an exploratory factor analysis on Positive and Negative Symptom Scale scores of 82 subjects with major depressive disorder and 76 subjects with organic brain disease (dementia or stroke).
RESULTS: The examination of the resultant symptom clusters revealed that the structure of the negative syndrome in major depressive disorder and organic brain disease closely corresponded to that in schizophrenia literature.
CONCLUSIONS: The negative syndrome may be a nosologic entity, which remains fairly consistent across psychotic and nonpsychotic diagnostic categories. Confirmatory studies are merited to determine the degree and strength of the similarity in structure of the negative syndrome in psychotic, affective, and cognitive illness.

Entities:  

Mesh:

Year:  2007        PMID: 17558255     DOI: 10.1097/WNN.0b013e3180653c35

Source DB:  PubMed          Journal:  Cogn Behav Neurol        ISSN: 1543-3633            Impact factor:   1.600


  5 in total

Review 1.  Comparisons of the tolerability and sensitivity of quetiapine-XR in the acute treatment of schizophrenia, bipolar mania, bipolar depression, major depressive disorder, and generalized anxiety disorder.

Authors:  Zuowei Wang; David E Kemp; Philip K Chan; Yiru Fang; Stephen J Ganocy; Joseph R Calabrese; Keming Gao
Journal:  Int J Neuropsychopharmacol       Date:  2010-09-29       Impact factor: 5.176

2.  An economic evaluation of a contingency-management intervention for stimulant use among community mental health patients with serious mental illness.

Authors:  Sean M Murphy; Michael G McDonell; Sterling McPherson; Debra Srebnik; Frank Angelo; John M Roll; Richard K Ries
Journal:  Drug Alcohol Depend       Date:  2015-05-14       Impact factor: 4.492

3.  Structural differences within negative and depressive syndrome dimensions in schizophrenia, organic brain disease, and major depression: A confirmatory factor analysis of the positive and negative syndrome scale.

Authors:  Daniel P Eisenberg; Dmitry B Aniskin; Leonard White; Judith A Stein; Philip D Harvey; Igor I Galynker
Journal:  Psychopathology       Date:  2009-05-16       Impact factor: 1.944

4.  Psychosis in behavioral variant frontotemporal dementia.

Authors:  Flora T Gossink; Everard Gb Vijverberg; Welmoed Krudop; Philip Scheltens; Max L Stek; Yolande Al Pijnenburg; Annemiek Dols
Journal:  Neuropsychiatr Dis Treat       Date:  2017-04-13       Impact factor: 2.570

Review 5.  Candidate Biomarkers of Suicide Crisis Syndrome: What to Test Next? A Concept Paper.

Authors:  Raffaella Calati; Charles B Nemeroff; Jorge Lopez-Castroman; Lisa J Cohen; Igor Galynker
Journal:  Int J Neuropsychopharmacol       Date:  2020-04-21       Impact factor: 5.176

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.